Jupiter Neurosciences Secures Flexible Financing Agreements Worth Up to $20 Million

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Oct 27 2025

0mins

Source: Globenewswire

Financing Agreements: Jupiter Neurosciences, Inc. has secured two strategic financing agreements with Yorkville Advisors, potentially accessing up to $20 million to support its Phase 2 trial for Parkinson's disease and to enhance its Nugevia™ product line.
Use of Proceeds: The funds will primarily be allocated to the Phase 2 trial of JOTROL™, a resveratrol delivery platform, and to boost direct-to-consumer marketing for Nugevia™, along with general corporate purposes.
Key Financing Terms: The financing includes a $6 million pre-paid advance and an additional $14 million available under a standby equity purchase agreement, with specific conditions for repayment and stock issuance.
Company Overview: Jupiter Neurosciences focuses on CNS disorders and consumer longevity products, leveraging its proprietary JOTROL™ formulation to improve bioavailability and support health in areas like cognitive function and skin vitality.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.